Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

NCT01186705 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Colon Cancer
Rectal Cancer

Interventions

DRUG: MK-2206

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]